Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174437 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3GBA1GRM2 | |
| SCHEMBL31372524 | 0.90 | RAB9A (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2042093 | 0.90 | RAB9A (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19493715 | 0.90 | RAB9A (0.50) | SLC6A2SLC6A4SLC6A3 | |
| Water SCHEMBL28259876 | 0.88 | RAB9A (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28263198 | 0.88 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL11249479 | 0.86 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL4762971 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3GBA1GRM2 | |
| SCHEMBL3636577 | 0.83 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3GBA1GRM2 | |
| SCHEMBL27397592 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576561-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220281797-A1 | KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220243001-A1 | EPOXY RESIN COMPOSITION | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2022-08-04 | — | — | US | disclosed |
| EP-2576561-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-100523897-C | Laser module | FUJI PHOTO FILM CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| CN-1604413-A | Laser module | FUJI PHOTO FILM CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| US-6495653-B1 | RETAINING CURABILITY EVEN AT A LOW TEMPERATURES, LOW VISCOSITY, RAPID CURE | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| JP-2002173658-A | RESIN COMPOSITION FOR ADHESION AND SEALING | FUJITSU LTD | 2002-06-21 | — | — | JP | disclosed |
| US-4965342-A | BRANCHED, ATACTIC, HIGHLY CRYSTALLINE | ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0345073-A1 | Poly (3-(Substituted)-3(Hydroxymethyl) oxetane) and method of preparing same | ARIZONA BOARD OF REGENTS (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0345074-A1 | High molecular weight polymers and copolymers of 3-hydroxyoxetane and derivatives thereof. | ARIZONA BOARD OF REGENTS (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4833183-A | FILMS, FIBERS, MOLDING MATERIALS EXPLOSIVES | ARIZONA BOARD OF REGENTS (US) | 1989-05-23 | — | — | US | disclosed |
| US-4047963-A | ETHYLENE OXIDE COPOLYMER, UNSATURATED MONOMER, PHOTOINITIATOR | HERCULES INCORPORATED (US) | 1977-09-13 | — | — | US | disclosed |
| US-4009128-A | Polymerization of epoxides | HERCULES INCORPORATED (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281797-A1 | KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF | PTGES, PTGIS, PTGES2 | SLC6A2 4695/4885SLC6A4 3856/4885SLC6A3 4729/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | SLC6A2 4674/4885SLC6A4 4696/4885SLC6A3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.